Healthcare

Hedge Fund Tycoon David Shaw Makes 2 Risky Bio Bets: MannKind Corporation (MNKD), Valeant Pharmaceuticals Intl Inc (VRX)

Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.

Can Synergy Pharmaceuticals Inc Get Things Moving Again with Trulance?

Wednesday could mark a turning point for Synergy investors.

4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)

Written by Danny Cohen and Scott Matusow The biotech “run-up” trade has always attracted a wide-array of traders looking to take advantage of …

A Growing Medical Device Player Aiming to Rule the $6.3 Billion Pain Market; An Exclusive Interview with Zynex CEO Thomas Sandgaard

Before founding Zynex, Inc. (OTCMKTS:ZYXI) over two decades ago, Thomas Sandgaard was a man who had just moved to the U.

Does Teva Pharmaceutical Industries Ltd (ADR) (TEVA) CEO Schultz Need a Bodyguard?

Is Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) “a ticking bomb” after new Danish CEO Kare Schultz has ordered a quarter of the Israeli …

Ex-Harvard Endowment Bosses Make Surprise Bet on Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Say Goodbye to Valeant Pharmaceuticals Intl Inc (VRX)

This billion-dollar hedge fund initiates new position in struggling pharma TEVA as exits VRX.

Illinois’ Richest Man Ken Griffin Sees Potential Opportunities in Healthcare: Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical Industries Ltd (TEVA)

Ken Griffin is a man known to be raring to take a risk when it is worthwhile, a daring and strategic mindset that …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts